Innovotech

Innovotech EBITDA Margin

The EBITDA Margin of Innovotech (IOT.V) as of Nov 21, 2026 is 2.68 %. In the previous year, EBITDA Margin was 4.07 % — a change of -34.17% (lower).

EBITDA Margin

2.68 %

YoY

-34.17%

Last updated:

EBITDA Margin of Innovotech is 2025 2.68 % . EBITDA Margin of Innovotech was 2024 4.07 % . It decreases by -34.17% lower compared to the previous year.

The Innovotech EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-15.36 CAD
Jan 1, 2019
-4.08 CAD
Jan 1, 2020
8.32 CAD
Jan 1, 2021
18.08 CAD
Jan 1, 2022
-12.48 CAD
Jan 1, 2023
-31.57 CAD
Jan 1, 2024
4.07 CAD
Jan 1, 2025
2.68 CAD
The Innovotech EBITDA Margin history
YEAREBITDA MarginYoY
2.68 %-34.17%
4.07 %-112.91%
-31.57 %+153.07%
-12.48 %-168.99%
18.08 %+117.29%
8.32 %-303.86%
-4.08 %-73.42%
-15.36 %-522.20%
3.64 %-57.50%
8.56 %-135.22%
-24.30 %+56.00%
-15.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innovotech Stock analysis

What does Innovotech do? Innovotech Inc. generates revenue through the sale of proprietary assay kits, including MBEC Assay Kits, Order Biofilm Assays, and Coated MBEC Assay Lids, which are used in microbial biofilm research. The company also provides contract research services such as Antimicrobial Contract Research, Antimicrobial and Anti-Biofilm Agents testing (MIC and MBEC), and Customized Antimicrobial Testing (BEST Assay Testing and Implanted Medical Device Testing). Its antimicrobial silver products, AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products, are sold to customers in agricultural and medical sectors. The firm targets research institutions, agricultural producers, and medical device manufacturers seeking biofilm and antimicrobial testing solutions. Innovotech's intellectual property portfolio supports its contract research services, which include testing for antimicrobial agents and materials under standards like TM100, ISO 22196, and USP 51. The company’s Biofilm Publications and SEM Library serve as additional resources for clients engaged in biofilm research. Its product offerings are tailored to sectors requiring microbial biofilm analysis, such as crop protection and medical device development, with AgreGuard-1 and InnovoSIL products specifically addressing antimicrobial needs in agriculture and medical applications. The company monetizes its proprietary technology through direct sales of assay kits and antimicrobial silver products, while contract research services provide recurring revenue streams. Clients include research organizations conducting biofilm studies, agricultural businesses using AgreGuard-1 for crop protection, and medical device manufacturers utilizing InnovoSIL for antimicrobial properties. Innovotech’s focus on specialized testing methodologies and branded products ensures consistent demand from niche markets requiring precise biofilm and antimicrobial evaluation. Innovotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innovotech stock

EBITDA Margin of Innovotech is 2.68 % in 2025.

EBITDA Margin of Innovotech changed from 4.07 % to 2.68 %, representing a -34.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Innovotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Innovotech with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Innovotech

All Key Metrics — Innovotech